Boxer Capital Management LLC Takes $28.19 Million Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Boxer Capital Management LLC bought a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,027,678 shares of the company's stock, valued at approximately $28,185,000. Tyra Biosciences makes up approximately 2.4% of Boxer Capital Management LLC's investment portfolio, making the stock its 10th biggest position. Boxer Capital Management LLC owned approximately 4.01% of Tyra Biosciences at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of TYRA. KLP Kapitalforvaltning AS bought a new stake in Tyra Biosciences during the fourth quarter worth $31,000. US Bancorp DE purchased a new position in shares of Tyra Biosciences in the 4th quarter worth about $50,000. Aquatic Capital Management LLC bought a new position in Tyra Biosciences during the fourth quarter valued at about $64,000. Wells Fargo & Company MN increased its holdings in Tyra Biosciences by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company's stock worth $132,000 after buying an additional 3,236 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its position in Tyra Biosciences by 130,587.5% in the fourth quarter. Russell Investments Group Ltd. now owns 10,455 shares of the company's stock worth $145,000 after acquiring an additional 10,447 shares during the period. Hedge funds and other institutional investors own 84.14% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Tyra Biosciences in a research note on Monday, March 31st. UBS Group assumed coverage on shares of Tyra Biosciences in a report on Tuesday, January 7th. They set a "buy" rating and a $28.00 price objective on the stock. Finally, Wedbush reissued an "outperform" rating and issued a $30.00 price target on shares of Tyra Biosciences in a research report on Friday, March 28th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $30.83.

Insider Activity at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 5,401 shares of the firm's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $13.76, for a total transaction of $74,317.76. Following the transaction, the director now directly owns 443,885 shares of the company's stock, valued at approximately $6,107,857.60. This trade represents a 1.20 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 15.40% of the stock is currently owned by insiders.

Tyra Biosciences Price Performance

NASDAQ:TYRA traded down $0.36 during trading hours on Monday, hitting $10.50. The stock had a trading volume of 124,353 shares, compared to its average volume of 253,850. The firm has a market capitalization of $557.45 million, a price-to-earnings ratio of -6.52 and a beta of 1.17. Tyra Biosciences, Inc. has a one year low of $6.42 and a one year high of $29.60. The company has a 50 day simple moving average of $9.77 and a two-hundred day simple moving average of $13.62.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.05. Equities research analysts anticipate that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.